New Hepatitis B Vaccine Developed

The Israeli drug manufacturer SciVac has developed a new third-generation hepatitis B vaccine that the company believes would halt global growth of the virus.

The medical community has used the current second-generation vaccine for more than 20 years; according to SciVac, 10 percent of newborns and 25 percent of adults older than 40 do not respond to it. SciVac Chief Executive Officer Michal Ben Attar stated that the new vaccine was 100-percent effective against hepatitis B.

The drug manufacturer has applied to the US Food and Drug Administration for permission to distribute the vaccine; if granted, SciVac also will seek approval in Europe.

The Friends of AIDS Foundation is dedicated to enhancing the quality of life for HIV positive individuals and empowering people to make healthy choices to prevent the spread of the HIV virus.

To learn more about The Friends of AIDS Foundation, please visit: http://www.friendsofaids.org.

TOGETHER WE REMAIN STRONG!